患哮喘的COVID-19幸存者的SARS-CoV-2特异性适应性免疫
2022/08/19
摘要
背景：哮喘患者对病毒感染的适应性免疫力可能受损。患有和不患有哮喘的COVID-19幸存者之间的SARS-COV-2特异性适应性免疫水平目前尚不清楚。
方法：纳入COVID-19幸存者(哮喘患者11例，过敏患者8例，仅COVID-19患者17例)和非COVID-19个体(哮喘患者10例，健康对照9例)。出院后8个月和16个月随访。分析SARS-CoV-2的临床特征、淋巴细胞亚群、记忆T细胞和体液免疫，包括SARS-CoV-2特异性抗体、SARS-CoV-2伪型病毒中和试验和记忆B细胞。
结果：八个月随访时发现COVID-19幸存者的病毒特异性T细胞反应强度与血嗜酸性粒细胞和Treg细胞比例呈正相关(r=0.4007,p=0.0188;r=0.4435,p=0.0086)。患有和不患有哮喘的COVID-19幸存者之间的SARS-COV-2特异性T细胞反应水平没有统计学差异。与没有哮喘的患者相比，COVID-19哮喘幸存者在8个月随访时的SARS-COV-2特异性中和抗体(NAbs)水平更高(P<0.05)。COVID-19存活者体内NAbs抗体水平与Treg和cTfh2细胞比例呈正相关(r =0.5037,p=0.02;r=0.4846,p=0.0141)，与Th1、Th17细胞比例(r=-0.5701,p=0.0003;和r =-0.3656,p=0.0308)、Th1/Th2、Th17Treg、cTfh1/cTfh2细胞比值(r=-0.5356、r=-0.5947、r=-0.4485;p<0.05)成负相关。在16个月的随访中，患有哮喘的COVID-19幸存者与没有哮喘的患者的NAbs衰减率没有显著差异。
结论：在随访8个月时，COVID-19幸存者中哮喘患者的SARS-COV-2特异性NAbs水平高于无哮喘患者。SARS-CoV-2特异性T细胞免疫与血液嗜酸性粒细胞和Treg百分率有关。SARS-COV-2特异性体液免疫与cTfh2/cTfh1失衡和Treg/Th17比例密切相关。研究发现，哮喘患者在COVID-19恢复期可能受益于增强的特异性体液免疫，这与Th2/Th1和Treg/Th17免疫倾斜有关。
SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma
Chen, Li; Yue, Junqing; Zhang, Shengding, et al
Abstract
BACKGROUND：Asthma patients potentially have impaired adaptive immunity to virus infection. The levels of SARS-CoV-2-specific adaptive immunity between COVID-19 survivors with and without asthma are presently unclear.
METHODS：COVID-19 survivors (patients with asthma n=11, with allergies n=8, and COVID-19 only n=17) and non-COVID-19 individuals (asthmatic patients n=10 and healthy controls n=9) were included. The COVID-19 patients were followed up at about 8 months and 16 months after discharge. The clinical characteristics, lymphocyte subsets, memory T cells, and humoral immunity including SARS-CoV-2 specific antibodies, SARS-CoV-2 pseudotyped virus neutralization assay, and memory B cells were analyzed in these subjects.
RESULTS：The strength of virus-specific T cell response in COVID-19 survivors was positively correlated with the percentage of blood eosinophils and Treg cells (r=0.4007, p=0.0188; and r=0.4435, p=0.0086 respectively) at 8-month follow-up. There were no statistical differences in the levels of SARS-CoV-2-specific T cell response between the COVID-19 survivors with, and without, asthma. Compared to those without asthma, the COVID-19 with asthma survivors had higher levels of SARS-CoV-2-specific neutralizing antibodies (NAbs) at the 8-month follow-up (P<0.05). Moreover, the level of NAbs in COVlD -19 survivors was positively correlated with the percentage of Treg and cTfh2 cells ( r =0.5037, p =0.02; and r =0.4846, p =0.0141), and negatively corelated with the percentage of Th1 and Th17 cells ( r =-0.5701, p =0.0003; and r =-0.3656, p =0.0308), the ratio of Th1/Th2,Th17Treg, and cTfh1/cTfh2 cell ( r =-0.5356, r =-0.5947, r =-0.4485; al p <0.05). The decay rate of NAbs in the COVID -19 survivors with asthma was not significantly different from that of those without asthma at 16-month follow-up.
CONCLUSIONS：The level of SARS-CoV-2-specific NAbs in COVID-19 survivors with asthma was higher than that of those without asthma at 8-month follow-up. The SARS-CoV-2- specific T cell immunity was associated with blood eosinophils and Treg percentages. The SARS-CoV-2-specific humoral immunity was closely associated with cTfh2/cTfh1 imbalance and Treg/Th17 ratio. According to the findings, asthmatic patients in COVID19 convalescent period may benefit from an enhanced specific humoral immunity, which associates with skewed Th2/Th1 and Treg/Th17 immune.
背景：哮喘患者对病毒感染的适应性免疫力可能受损。患有和不患有哮喘的COVID-19幸存者之间的SARS-COV-2特异性适应性免疫水平目前尚不清楚。
方法：纳入COVID-19幸存者(哮喘患者11例，过敏患者8例，仅COVID-19患者17例)和非COVID-19个体(哮喘患者10例，健康对照9例)。出院后8个月和16个月随访。分析SARS-CoV-2的临床特征、淋巴细胞亚群、记忆T细胞和体液免疫，包括SARS-CoV-2特异性抗体、SARS-CoV-2伪型病毒中和试验和记忆B细胞。
结果：八个月随访时发现COVID-19幸存者的病毒特异性T细胞反应强度与血嗜酸性粒细胞和Treg细胞比例呈正相关(r=0.4007,p=0.0188;r=0.4435,p=0.0086)。患有和不患有哮喘的COVID-19幸存者之间的SARS-COV-2特异性T细胞反应水平没有统计学差异。与没有哮喘的患者相比，COVID-19哮喘幸存者在8个月随访时的SARS-COV-2特异性中和抗体(NAbs)水平更高(P<0.05)。COVID-19存活者体内NAbs抗体水平与Treg和cTfh2细胞比例呈正相关(r =0.5037,p=0.02;r=0.4846,p=0.0141)，与Th1、Th17细胞比例(r=-0.5701,p=0.0003;和r =-0.3656,p=0.0308)、Th1/Th2、Th17Treg、cTfh1/cTfh2细胞比值(r=-0.5356、r=-0.5947、r=-0.4485;p<0.05)成负相关。在16个月的随访中，患有哮喘的COVID-19幸存者与没有哮喘的患者的NAbs衰减率没有显著差异。
结论：在随访8个月时，COVID-19幸存者中哮喘患者的SARS-COV-2特异性NAbs水平高于无哮喘患者。SARS-CoV-2特异性T细胞免疫与血液嗜酸性粒细胞和Treg百分率有关。SARS-COV-2特异性体液免疫与cTfh2/cTfh1失衡和Treg/Th17比例密切相关。研究发现，哮喘患者在COVID-19恢复期可能受益于增强的特异性体液免疫，这与Th2/Th1和Treg/Th17免疫倾斜有关。
（中日友好医院呼吸与危重症医学科 李春晓 摘译 林江涛 审校）
（Front. Immunol, 18 July 2022 https://doi.org/10.3389/fimmu.2022.947724）
（Front. Immunol, 18 July 2022 https://doi.org/10.3389/fimmu.2022.947724）
SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma
Chen, Li; Yue, Junqing; Zhang, Shengding, et al
Abstract
BACKGROUND：Asthma patients potentially have impaired adaptive immunity to virus infection. The levels of SARS-CoV-2-specific adaptive immunity between COVID-19 survivors with and without asthma are presently unclear.
METHODS：COVID-19 survivors (patients with asthma n=11, with allergies n=8, and COVID-19 only n=17) and non-COVID-19 individuals (asthmatic patients n=10 and healthy controls n=9) were included. The COVID-19 patients were followed up at about 8 months and 16 months after discharge. The clinical characteristics, lymphocyte subsets, memory T cells, and humoral immunity including SARS-CoV-2 specific antibodies, SARS-CoV-2 pseudotyped virus neutralization assay, and memory B cells were analyzed in these subjects.
RESULTS：The strength of virus-specific T cell response in COVID-19 survivors was positively correlated with the percentage of blood eosinophils and Treg cells (r=0.4007, p=0.0188; and r=0.4435, p=0.0086 respectively) at 8-month follow-up. There were no statistical differences in the levels of SARS-CoV-2-specific T cell response between the COVID-19 survivors with, and without, asthma. Compared to those without asthma, the COVID-19 with asthma survivors had higher levels of SARS-CoV-2-specific neutralizing antibodies (NAbs) at the 8-month follow-up (P<0.05). Moreover, the level of NAbs in COVlD -19 survivors was positively correlated with the percentage of Treg and cTfh2 cells ( r =0.5037, p =0.02; and r =0.4846, p =0.0141), and negatively corelated with the percentage of Th1 and Th17 cells ( r =-0.5701, p =0.0003; and r =-0.3656, p =0.0308), the ratio of Th1/Th2,Th17Treg, and cTfh1/cTfh2 cell ( r =-0.5356, r =-0.5947, r =-0.4485; al p <0.05). The decay rate of NAbs in the COVID -19 survivors with asthma was not significantly different from that of those without asthma at 16-month follow-up.
CONCLUSIONS：The level of SARS-CoV-2-specific NAbs in COVID-19 survivors with asthma was higher than that of those without asthma at 8-month follow-up. The SARS-CoV-2- specific T cell immunity was associated with blood eosinophils and Treg percentages. The SARS-CoV-2-specific humoral immunity was closely associated with cTfh2/cTfh1 imbalance and Treg/Th17 ratio. According to the findings, asthmatic patients in COVID19 convalescent period may benefit from an enhanced specific humoral immunity, which associates with skewed Th2/Th1 and Treg/Th17 immune.
上一篇：
过敏性致敏损害肺部常驻记忆CD8 T细胞反应和病毒清除
下一篇：
锌指蛋白33B在儿童哮喘中的与特应性相关标志物的性相互作用
